Lisata reports Q3 2025 net loss $4.2M; cash runway into Q1 2027 with new partnerships

LISATA THERAPEUTICS, INC.

2025-Q3 EPS reported -$1.58 revenue$70,000

Net loss $4.2M vs $4.9M in Q3 2024; operating expenses down 17% to $4.4M.
Cash and equivalents $19.0M; management projects funding operations into Q1 2027.
ASCEND mPDAC trial final data expected Q1 2026; BOLSTER topline data due Q4 2025.
Licensed certepetide to Catalent for ADC platform; partnered with GATC Health for AI drug discovery.
Preliminary CENDIFOX data showed 70% pathologic partial response and 60% 2-year OS in PDAC cohort.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.